Company Study of Walvax Biotechnology Co, Ltd., 2012

April 2012 | 13 pages | ID: C39020B5781EN
ResearchInChina

Abstracts

Walvax Biotechnology Co, Ltd. (Walvax Biotechnology for short), founded in 2001, specializes in research & development, production and marketing of bio-pharmaceutical vaccines. In September 2010, it went public on the Shenzhen's Growth Enterprise Market (GEM), with the approval of China Securities Regulatory Commission (CSRC). Walvax Biotechnology employs about 863 people, including 161 for research and development. It has new-type vaccine research & development center and pilot base at Kunming High-tech Industrial Development Zone (located in Kunming, Yunnan province) as well as vaccine production bases at Yuxi Hi-Tech & New Industrial Development Zone (located in Yuxi, Yunnan province) and Taizhou National Medical Hi-Tech Development Zone (located in Taizhou, Jiangsu province). In addition, its marketing network covers 30 provinces or cities and more than 2000 regions or counties throughout China

Contents

1 PROFILE

2 OPERATION

3 REVENUE STRUCTURE

4 GROSS MARGIN

5 CLIENT AND SUPPLIER

6 R&D AND INVESTMENT

Selected Charts

SELECTED CHARTS

Vaccines on the Market and Capacity of Walvax Biotechnology
Revenue and Income of Walvax Biotechnology, 2007-2011
Revenue Breakdown of Walvax Biotechnology by Products, 2007-2011
Lot Release Quantity and Proportion of Walvax Biotechnology by Products, 2009-2012
Revenue Breakdown of Walvax Biotechnology by Region, 2010-2011
Gross Margin of Walvax Biotechnology, 2007-2011
Walvax Biotechnology’s Revenue from Top 5 Clients and % of Total Revenue, 2007-2011
Top5 Clients and Their Revenue of Walvax Biological, 2011
Walvax Biological’s Procurement from Top 5 Suppliers and % of Total Procurement, 2007-2011
Top5 Suppliers and Their Procurement Value of Walvax Biological, 2011
R&D Expenditure and Its Proportion to Revenue of Walvax Biotechnology, 2009-2011
New Vaccine Schedule of Walvax Biological as of March 31, 2012